Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways

Figure 8 Model of allyl isothiocyanate action. Schematic diagram: allyl isothiocyanate ameliorates hepatic lipid accumulation and hepatic inflammation by activating the Sirt1/AMPK signaling pathway and inhibiting the NF-κB pathway. AITC: Allyl isothiocyanate; IKK: IκB kinase; IκBα: Inhibitor of nuclear factor kappa B α; TNFα: Tumor necrosis factor α; IL-6: Interleukin-6; IL-1β: Interleukin-1β; Sirt1: Sirtuin 1; AMPKα: AMP-activated protein kinase α; PGC1α: Proliferator-activated receptor gamma coactivator 1α; PPARα: Peroxisome proliferator-activated receptor α; CPT1α: Carnitine palmitoyltransferase 1 α; SREBP1: Sterol regulatory element­binding protein 1; SCD1: Stearoyl coenzyme A desaturase 1; FAS: Fatty acid synthase; ACC1: Acetyl-CoA carboxylase 1.